This symposium, held during the 2025 AANEM Annual Meeting, explores the clinical integration of neonatal Fc receptor (FcRn) antagonists in the management of generalized myasthenia gravis. Faculty review the mechanistic rationale and clinical trial data, with a focus on differences in onset, duration, administration, and tolerability among therapies.
The session also addresses how antibody profiles and diagnostic criteria inform treatment decisions, along with practical considerations such as use in special populations, plasma exchange compatibility, and vaccination timing. Expert-led discussions will offer actionable insights for optimizing FcRn therapy across diverse clinical settings.
This activity is not part of the official scientific program of the AANEM.
Advancing Myasthenia Gravis (MG) Treatment Through Guideline Updates and Emerging Therapies
Explore FcRn antagonists in gMG with expert insights on mechanisms, trial data, clinical use, and personalized treatment considerations.
333 O'Farrell St., Imperial Ballroom (Ballroom Level), San Francisco, California, United States
Overview
Program Schedule*
11:30am – 11:45am: Registration and Lunch
11:45am – 11:50am: Welcome and Introductions
11:50am – 12:05pm: Targeting the Receptor - FcRn Antagonists in gMG: Mechanisms, Safety, and Efficacy
12:05pm – 12:20pm: Precision in Practice: Personalizing FcRn Therapy Through Diagnostic and Serologic Insights
12:20pm – 12:35pm: Practical Pearls: Real-World Considerations for FcRn Use in Complex Clinical Settings
12:35pm – 12:45pm: Summary and Audience Q&A
*Subject to changeDisclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Pushpa Narayanaswami, MD, FAAN
Professor of Clinical Neurology
Harvard Medical School
Vice-Chair, Clinical Operations
Dept. of Neurology
Beth Israel Deaconess Medical Center
Boston, MA
Dr. Narayanaswami has no relevant relationships to disclose.
Faculty:
Srikanth Muppidi, MD
Clinical Professor, Adult Neurology
Stanford University School of Medicine
Stanford, CA
Dr. Muppidi has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consultant: Alexion, Amgen, Argenx, Johnson & Johnson, Kyverna, Novartis, UCB
Gil I. Wolfe, MD, FAAN
SUNY Distinguished Professor
Co-Director, Neuromuscular/MDA Program
Dept. of Neurology, Jacobs School of Medicine and Biomedical Sciences
Univ. at Buffalo/SUNY
Buffalo, NY
Dr. Wolfe has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consultant: Alexion, Argenx, Cartesian, Johnson & Johnson, Takeda, UCB
Research: Argenx, Immunovant
Reviewers/Content Planners/Authors:- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
- Tim Person has no relevant relationships to disclose.
- Parul Yadav, MD, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Evaluate FcRn antagonist in the treatment of gMG based on their mechanism of action and clinical trial evidence.
- Apply diagnostic criteria and antibody profiles to guide personalized selection and use of FcRn-targeted therapies in patients with gMG.
- Identify key clinical considerations for FcRn antagonist use, including management in special populations, compatibility with plasma exchange, and vaccination timing.
Target Audience
This activity has been designed to meet the educational needs of neurologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with Myasthenia Gravis (MG).
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-084-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.Commercial Support
This activity is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
Overview
This symposium, held during the 2025 AANEM Annual Meeting, explores the clinical integration of neonatal Fc receptor (FcRn) antagonists in the management of generalized myasthenia gravis. Faculty review the mechanistic rationale and clinical trial data, with a focus on differences in onset, duration, administration, and tolerability among therapies.
The session also addresses how antibody profiles and diagnostic criteria inform treatment decisions, along with practical considerations such as use in special populations, plasma exchange compatibility, and vaccination timing. Expert-led discussions will offer actionable insights for optimizing FcRn therapy across diverse clinical settings.
This activity is not part of the official scientific program of the AANEM.Program Schedule*
11:30am – 11:45am: Registration and Lunch
11:45am – 11:50am: Welcome and Introductions
11:50am – 12:05pm: Targeting the Receptor - FcRn Antagonists in gMG: Mechanisms, Safety, and Efficacy
12:05pm – 12:20pm: Precision in Practice: Personalizing FcRn Therapy Through Diagnostic and Serologic Insights
12:20pm – 12:35pm: Practical Pearls: Real-World Considerations for FcRn Use in Complex Clinical Settings
12:35pm – 12:45pm: Summary and Audience Q&A
*Subject to changeDisclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Pushpa Narayanaswami, MD, FAAN
Professor of Clinical Neurology
Harvard Medical School
Vice-Chair, Clinical Operations
Dept. of Neurology
Beth Israel Deaconess Medical Center
Boston, MA
Dr. Narayanaswami has no relevant relationships to disclose.
Faculty:
Srikanth Muppidi, MD
Clinical Professor, Adult Neurology
Stanford University School of Medicine
Stanford, CA
Dr. Muppidi has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consultant: Alexion, Amgen, Argenx, Johnson & Johnson, Kyverna, Novartis, UCB
Gil I. Wolfe, MD, FAAN
SUNY Distinguished Professor
Co-Director, Neuromuscular/MDA Program
Dept. of Neurology, Jacobs School of Medicine and Biomedical Sciences
Univ. at Buffalo/SUNY
Buffalo, NY
Dr. Wolfe has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consultant: Alexion, Argenx, Cartesian, Johnson & Johnson, Takeda, UCB
Research: Argenx, Immunovant
Reviewers/Content Planners/Authors:- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
- Tim Person has no relevant relationships to disclose.
- Parul Yadav, MD, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Evaluate FcRn antagonist in the treatment of gMG based on their mechanism of action and clinical trial evidence.
- Apply diagnostic criteria and antibody profiles to guide personalized selection and use of FcRn-targeted therapies in patients with gMG.
- Identify key clinical considerations for FcRn antagonist use, including management in special populations, compatibility with plasma exchange, and vaccination timing.
Target Audience
This activity has been designed to meet the educational needs of neurologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with Myasthenia Gravis (MG).
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-084-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.Commercial Support
This activity is supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
Recommended
Paul Petrakos, DO, MS
Justin Schweitzer, OD, FAAO
I. Paul Singh, MD
Sarah H. Van Tassel, MD
0.25 credits
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
CME/CETreatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
0.75 creditsVera Bril, MD
Neelam Goyal, MD
0.75 creditsRevolutionizing Diagnostic Precision: AI-Driven Approaches in Digital Pathology and HER2 Expression
Revolutionizing Diagnostic Precision: AI-Driven Approaches in Digital Pathology and HER2 Expression
CME/CERevolutionizing Diagnostic Precision: AI-Driven Approaches in Digital Pathology and HER2 Expression
0.50 creditsMarilyn Yuanxin Ma Bui, MD, PhD
Anne Vincent-Salomon, MD
0.50 creditsPreventing Myasthenic Crisis: Early Signs and Critical Interventions
Preventing Myasthenic Crisis: Early Signs and Critical Interventions
MinuteCE®Preventing Myasthenic Crisis: Early Signs and Critical Interventions
1.00 program creditVera Bril, MD
Hans Katzberg, MD
1.00 program credit